Ossifying fibroma of the jaw bones in hyperparathyroidism-jaw tumor syndrome: Analysis of 24 cases retrieved from literatures
- PMID: 33505612
- PMCID: PMC7816022
- DOI: 10.1016/j.jds.2019.12.007
Ossifying fibroma of the jaw bones in hyperparathyroidism-jaw tumor syndrome: Analysis of 24 cases retrieved from literatures
Abstract
Background/purpose: Hyperparathyroidism-jaw tumor syndrome is a rare autosomal dominant disease characterized by parathyroid tumors and ossifying fibroma of the jaw. Disease-causing mutations have been localized in the tumor suppressor gene CDC73. This study is designed to highlight the importance of genetic testing in the diagnosis of ossifying fibroma related to this syndrome.
Materials and methods: The Clinical, histopathological, radiographical, familial and genetic features of 24 patients with Hyperparathyroidism-jaw tumor syndrome were collected by searching the electronic literature PubMed, Medline, Embase, and Science Direct databases combining the MeSH heading terms "Hyperparathyroidism jaw tumor syndrome", with the words "Ossifying fibroma" and "CDC73". The collected features were simply assessed and analyzed.
Results: The average age was 28.68 years old (age range 10-66), with 12 male and 12 female patients (1:1 M/F ratio). Hyperparathyroidism results from parathyroid adenoma in 16/24 cases (66.666%) and parathyroid carcinome in 5/24 (20.833%). Bone pathology occurred most often in the mandible (16/24 cases; 66.666%), while 5/24 cases were in the maxilla (20.883%) and 3 cases in both (12.5%). In 5/24 cases, ossifying fibroma was the first to occur before hypercalcemia. Genetic mutation of CDC73 were positive in 19/24 cases (79.166%).
Conclusion: Since the jaw lesions in Hyperparathyroidism-jaw tumor syndrome could proceed the cardinal signs of hyperparathyroidism, its accurate diagnosis needs to depend on clinical, histological, radiographical, family history and most of all the genetic testing for CDC73 gene.
Keywords: CDC73; Hyperparathyroidism-jaw tumor syndrome; Mandible; Maxilla; Ossifying fibroma.
© 2020 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V.
Conflict of interest statement
None to declare.
Similar articles
-
Insights into Hyperparathyroidism-Jaw Tumour Syndrome: From Endocrine Acumen to the Spectrum of CDC73 Gene and Parafibromin-Deficient Tumours.Int J Mol Sci. 2024 Feb 15;25(4):2301. doi: 10.3390/ijms25042301. Int J Mol Sci. 2024. PMID: 38396977 Free PMC article. Review.
-
A Novel Mutation in a Patient with Hyperparathyroidism-Jaw Tumour Syndrome.Endocr Pathol. 2016 Jun;27(2):142-6. doi: 10.1007/s12022-016-9427-6. Endocr Pathol. 2016. PMID: 26995009
-
Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.J Oral Maxillofac Surg. 2015 Jan;73(1):194.e1-9. doi: 10.1016/j.joms.2014.09.008. Epub 2014 Sep 28. J Oral Maxillofac Surg. 2015. PMID: 25511968 Review.
-
Early-onset, severe, and recurrent primary hyperparathyroidism associated with a novel CDC73 mutation.Endocr J. 2015;62(7):627-32. doi: 10.1507/endocrj.EJ15-0057. Epub 2015 May 8. Endocr J. 2015. PMID: 25959515
-
A large extended family with hyperparathyroidism-jaw tumor syndrome due to deletion of the third exon of CDC73: clinical and molecular features.Endocrine. 2021 Sep;73(3):693-701. doi: 10.1007/s12020-021-02756-4. Epub 2021 May 17. Endocrine. 2021. PMID: 33999366
Cited by
-
A family case report of parathyroid carcinoma associated with CDC73 mutation in hyperparathyroidism-jaw tumor syndrome.Front Endocrinol (Lausanne). 2024 Jan 29;15:1330185. doi: 10.3389/fendo.2024.1330185. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38348418 Free PMC article.
-
Craniofacial disorders and dysplasias: Molecular, clinical, and management perspectives.Bone Rep. 2024 Mar 1;20:101747. doi: 10.1016/j.bonr.2024.101747. eCollection 2024 Mar. Bone Rep. 2024. PMID: 38566929 Free PMC article. Review.
-
A two-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family: clinical presentations, pathological characteristics and genetic analysis: a case report.Diagn Pathol. 2022 Sep 24;17(1):71. doi: 10.1186/s13000-022-01248-x. Diagn Pathol. 2022. PMID: 36153594 Free PMC article.
-
Insights into Hyperparathyroidism-Jaw Tumour Syndrome: From Endocrine Acumen to the Spectrum of CDC73 Gene and Parafibromin-Deficient Tumours.Int J Mol Sci. 2024 Feb 15;25(4):2301. doi: 10.3390/ijms25042301. Int J Mol Sci. 2024. PMID: 38396977 Free PMC article. Review.
-
Hyperparathyroidism-Jaw Tumor Syndrome: A Rare Case Report and Literature Review.Clin Case Rep. 2025 Apr 1;13(4):e70390. doi: 10.1002/ccr3.70390. eCollection 2025 Apr. Clin Case Rep. 2025. PMID: 40177159 Free PMC article.
References
-
- Villablanca A., Hoog A., Larsson C. Molecular genetics of familial hyperparathyroidism. J Endocr Genet. 2001;2:3–12.
-
- Marx S., Simonds W., Agarwal S. Hyperparathyroidism in hereditary syndromes: special expressions and special managements. J Bone Miner Res. 2002;17(suppl 2):N37–N43. - PubMed
-
- Bradley K.J., Cavaco B.M., Bowl M.R. Parafibromin mutations in hereditary hyperparathyroid syndrromes and parathyroid tumors. Clin Endocrinol. 2006;64:299–306. - PubMed
-
- Chen J.D., Morrison C., Zhang C. Hypcrparathyroidisin-jaw tumour syndrome. J Intern Med. 2003;253:634–642. - PubMed
-
- Speight P.M., Carlos R. Maxillofacial fibro-osseous lesions. Curr Diagn Pathol. 2006;12:1–10.
LinkOut - more resources
Full Text Sources